Basic information
- CAS
38562-01-5- Standard SMILES
CCCCC[C@H](O)/C=C/[C@@H]1[C@@H](C/C=C\CCCC(=O)O)[C@@H](O)C[C@H]1O.NC(CO)(CO)CO- InChIKey
IYGXEHDCSOYNKY-RZHHZEQLSA-N- Molecular formula
- C24H45NO8
- Average molar mass
- 475.6 g/mol
- Monoisotopic mass
- 475.31451739
Overview
Dinoprost tromethamine is an organic molecular entity.
Names & identifiers
- Preferred name
- Dinoprost Tromethamine
- IUPAC
- 2-amino-2-(hydroxymethyl)propane-1,3-diol;(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid
- English name
- Dinoprost tromethamine
- Molecular formula
- C24H45NO8
- Molecular weight
- 475.62
Names & synonyms
dinoprost tromethamine38562-01-5Dinoprost trometamolProstin F2 alphaPGF2alpha THAMLutalysePGF2-alpha thamProstaglandin F2alpha thamProstaglandin F2-alpha THAMProstamateProstaglandin F2a tromethaminePGF2A THAM
Show more names
prostaglandin f2a tris salt583eu14585PGF2αTrisEnsaprostPGF2ALPHAZinoprostPGF2a-THAM
U-14,583EPGF2ALPHA-THAMDTXSID1045582CT6BBQ5A68NSC-196515U-14583EU-14-583EDTXCID101476499
Database identifiers
- CAS
38562-01-5- PubChem CID
- 5282415
- DTXSID
DTXSID1045582- ChEMBL
CHEMBL1200896- ChEBI
CHEBI:31502- UNII
- CT6BBQ5A68
Properties
Computed structural properties
- Topological polar surface area
- 185 Ų
- Hydrogen bond donors
- 8
- Hydrogen bond acceptors
- 9
- Rotatable bonds
- 15
- Heavy atoms
- 33
- Formal charge
- 0
- Complexity
- 486
Experimental & physicochemical properties
Human Drugs
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Animal DrugsFDA approved animal drugs -> Active ingredient
Melting Point100-101
Physicochemical properties
- Melting point
- 100 · 100-101°
- storage temp.
- -20 °C · -20°C
- solubility
- 2 O: · H2O: 1 mg/mL Aqueous solutions are stable for 30 days at 2-8°C and for several months frozen at −0°C in single use aliquots. Avoid repeated freeze/thaw cycles.
- form
- powder
- color
- white
- biological source
- synthetic
- Water Solubility
- 2 O: · H2O: 1mg/mLethanol: 50mg/mL
- Merck
- 13 · 13,7970
- BRN
- 4087514 · 4087514
- Stability
- Hygroscopic
Safety & regulation
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
GHS classification
GHS Classification
Danger
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P203, P264, P264+P265, P270, P280, P301+P317, P305+P351+P338, P318, P330, P337+P317, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 71 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Hazard information
Regulatory InformationDinoprost tromethamine: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
Other Safety InformationIMAP assessments - Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-, (5Z,9.alpha.,11.alpha.,13E,15S)-, compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1): Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (100%)
Safety data
- F
- 8-10
- PPE
- Eyeshields, Gloves, type P3 (EN 143) respirator cartridges
- wgk
- 3
- rtecs
- UK8025000
- hs_code
- 2937500000
- risk_code
- 60-22
- Signal word
- Danger
- Symbol(GHS)
- GHS07,GHS08
- hazard_code
- T
Chemistry & industry
Pharmacology
Pharmacodynamics
Dinoprost tromethamine is the tromethamine (THAM) salt of the naturally occurring prostaglandin F2<sub>alpha</sub>. Prostaglandin F2<sub>alpha</sub> has several pharmacologic effects on the female reproductive system, including stimulation of myometrial activity, relaxation of the cervix, inhibition of steroidogenesis by corpora lutea, and can potentially lyse corpora lutea.
Mechanism of Action
Dinoprost tromethamine appears to act directly on the myometrium, but this has not been completely established. Dinoprost stimulates myometrial contractions (via its interaction with the prostaglandin receptors) in the gravid uterus that are similar to the contractions that occur in the term uterus during labor. These contractions are usually sufficient to cause abortion. Uterine response to prostaglandins increases gradually throughout pregnancy. Dinoprost also facilitates cervical dilatation and softening.
Biological Half-LifeThe half-life of dinoprost in amniotic fluid is 3 to 6 hours. The plasma half-life of dinoprost after intravenous administration is reported to be less than 1 minute.
Metabolism/MetabolitesEnzymatic dehydrogenation primarily in the maternal lungs and also in the liver.
MeSH Pharmacological Classification
Non-steroidal chemical compounds with abortifacient activity.
Drugs that stimulate contraction of the myometrium. They are used to induce LABOR, OBSTETRIC at term, to prevent or control postpartum or postabortion hemorrhage, and to assess fetal status in high risk pregnancies. They may also be used alone or with other drugs to induce abortions (ABORTIFACIENTS). Oxytocics used clinically include the neurohypophyseal hormone OXYTOCIN and certain prostaglandins and ergot alkaloids. (From AMA Drug Evaluations, 1994, p1157)
Absorption, Distribution and ExcretionSlowly absorbed from the amniotic fluid into systemic circulation.
Applications
Related reactions
0 records
No reaction records under the current filter.
Compound notes
Loading…